Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
1.
Turk J Med Sci ; 53(3): 780-790, 2023 06.
Artículo en Inglés | MEDLINE | ID: mdl-37476892

RESUMEN

BACKGROUND: To have country-wide information about multidrug resistance (MDR) in isolates from community-acquired urinary tract infections (CAUTI) of Turkey, in terms of resistance rates and useful options. METHODS: We used a geocode standard, nomenclature of territorial units for statistics (NUTS), and a total of 1588 community-acquired isolates of 20 centres from 12 different NUTS regions between March 2019 and March 2020 were analysed. RESULTS: Of the 1588 culture growths, 1269 (79. 9%) were Escherichia coli and 152 (9.6%) were Klebsiella spp. Male sex, advancedage, and having two or more risk factors showed a statistically significant relation with MDR existence (p < 0.001, p: 0.014, p < 0.001, respectively) that increasing number of risk factors or degree of advancing in age directly affects the number of antibiotic groups detected to have resistance by pathogens. In total, MDR isolates corresponded to 36.1% of our CAUTI samples; MDR existence was 35.7% in E. coli isolates and 57.2% in Klebsiella spp. isolates. Our results did not show an association between resistance or MDR occurrence rates and NUTS regions. DISCUSSION: The necessity of urine culture in outpatient clinics should be taken into consideration, at least after evaluating risk factorsfor antibacterial resistance individually. Community-acquired UTIs should be followed up time- and region-dependently. Antibiotic stewardship programmes should be more widely and effectively administrated.


Asunto(s)
Infecciones Comunitarias Adquiridas , Infecciones por Escherichia coli , Esclerosis Múltiple Recurrente-Remitente , Esclerosis Múltiple , Infecciones Urinarias , Humanos , Masculino , Escherichia coli , Infecciones por Escherichia coli/microbiología , Esclerosis Múltiple Recurrente-Remitente/complicaciones , Universidades , Farmacorresistencia Bacteriana Múltiple , Infecciones Urinarias/tratamiento farmacológico , Infecciones Urinarias/epidemiología , Infecciones Comunitarias Adquiridas/tratamiento farmacológico , Infecciones Comunitarias Adquiridas/epidemiología , Infecciones Comunitarias Adquiridas/microbiología , Klebsiella , Antibacterianos/uso terapéutico , Antibacterianos/farmacología , Pruebas de Sensibilidad Microbiana
2.
Health Qual Life Outcomes ; 14(1): 153, 2016 Nov 03.
Artículo en Inglés | MEDLINE | ID: mdl-27809934

RESUMEN

BACKGROUND: The aim of this study was to assess health-related quality of life (HRQOL) among chronic hepatitis B (CHB) patients in Turkey and to study related factors. METHODS: This multicenter study was carried out between January 01 and April 15, 2015 in Turkey in 57 centers. Adults were enrolled and studied in three groups. Group 1: Inactive HBsAg carriers, Group 2: CHB patients receiving antiviral therapy, Group 3: CHB patients who were neither receiving antiviral therapy nor were inactive HBsAg carriers. Study data was collected by face-to-face interviews using a standardized questionnaire, Short Form-36 (SF-36) and Hepatitis B Quality of Life (HBQOL). Values equivalent to p < 0.05 in analyses were accepted as statistically significant. RESULTS: Four thousand two hundred fifty-seven patients with CHB were included in the study. Two thousand five hundred fifty-nine (60.1 %) of the patients were males. Groups 1, 2 and 3, consisted of 1529 (35.9 %), 1721 (40.4 %) and 1007 (23.7 %) patients, respectively. The highest value of HRQOL was found in inactive HBsAg carriers. We found that total HBQOL score increased when antiviral treatment was used. However, HRQOL of CHB patients varied according to their socio-demographic properties. Regarding total HBQOL score, a higher significant level of HRQOL was determined in inactive HBV patients when matched controls with the associated factors were provided. CONCLUSIONS: The HRQOL score of CHB patients was higher than expected and it can be worsen when the disease becomes active. Use of an antiviral therapy can contribute to increasing HRQOL of patients.


Asunto(s)
Hepatitis B Crónica , Calidad de Vida , Adulto , Anciano , Antivirales/uso terapéutico , Estudios Transversales , Femenino , Indicadores de Salud , Hepatitis B Crónica/tratamiento farmacológico , Hepatitis B Crónica/psicología , Humanos , Entrevistas como Asunto , Masculino , Persona de Mediana Edad , Estudios Prospectivos , Turquía
3.
Scand J Infect Dis ; 42(10): 741-6, 2010 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-20500117

RESUMEN

The incidence, clinical characteristics, risk factors, antimicrobial susceptibility, and outcomes of nosocomial imipenem-resistant A. baumannii (IRAB) infections during a 5-y period (2003-2007) were retrospectively analyzed. A total of 720 patients with 925 episodes of A. baumannii infection were included in the study. A. baumannii infections were seen mostly in intensive care units. The incidence was 6.2 per 1000 admissions. The most common infections were pneumonias and bloodstream infections. Imipenem resistance among Acinetobacter strains increased significantly each y of the study (from 43.3% to 72.9%). Mortality was related to the presence of imipenem resistance, stay in intensive care unit, female gender, old age, and pneumonia. Haemodialysis, malignancy, and mechanical ventilation were significant risk factors for IRAB infections. Imipenem resistance was higher in strains isolated from patients with pneumonia. IRAB strains showed higher resistance rates to other antibiotics than imipenem-susceptible strains. The most active antimicrobial agents against A. baumannii were cefoperazone-sulbactam and netilmicin. The incidence of A. baumannii infections and imipenem resistance increased during the study period. IRAB infections should be considered in patients on mechanical ventilation and haemodialysis and in patients with malignancies.


Asunto(s)
Infecciones por Acinetobacter/epidemiología , Acinetobacter baumannii/efectos de los fármacos , Antibacterianos/farmacología , Infección Hospitalaria/epidemiología , Farmacorresistencia Bacteriana , Imipenem/farmacología , Infecciones por Acinetobacter/microbiología , Infecciones por Acinetobacter/mortalidad , Infecciones por Acinetobacter/fisiopatología , Acinetobacter baumannii/aislamiento & purificación , Adulto , Anciano , Antibacterianos/uso terapéutico , Bacteriemia/epidemiología , Bacteriemia/microbiología , Bacteriemia/fisiopatología , Infección Hospitalaria/microbiología , Infección Hospitalaria/mortalidad , Infección Hospitalaria/fisiopatología , Femenino , Humanos , Imipenem/uso terapéutico , Incidencia , Unidades de Cuidados Intensivos , Masculino , Pruebas de Sensibilidad Microbiana , Persona de Mediana Edad , Neumonía Bacteriana/epidemiología , Neumonía Bacteriana/microbiología , Neumonía Bacteriana/fisiopatología , Respiración Artificial/efectos adversos , Factores de Riesgo
4.
J Infect Dev Ctries ; 3(4): 273-7, 2009 May 01.
Artículo en Inglés | MEDLINE | ID: mdl-19759490

RESUMEN

BACKGROUND: Burkholderia cepacia has the potential to cause fatal infections in ICUs, and multidrug resistance makes them a serious threat in hospital settings. The aim of this study was to evaluate the epidemiology of B. cepacia infections in our hospital. METHODOLOGY: The incidence, clinical characteristics, antimicrobial susceptibility, and outcomes of nosocomial B. cepacia infections during a five-year period were retrospectively analysed according to the infection control committee records. RESULTS: A total of 39 cases with nosocomial B. cepacia infection were included in the study. B. cepacia was identified from 0.7% of the nosocomial isolates. Its incidence was 0.26 per 1,000 admissions with 53.8% crude mortality rate. The most frequent nosocomial B. cepacia infection was pneumonia (58.9%), followed by bloodstream infections (25.6%), surgical site infections (7.6%), urinary tract infections, (5.1%), and skin-soft tissue infections (2.5%). Nosocomial B. cepacia infections were most commonly observed in intensive care units (61.5%). The most active antimicrobial agents were piperacillin-tazobactam, cefoperazone-sulbactam, and carbapenems. CONCLUSIONS: The incidence of nosocomial B. cepacia infections was rare in our hospital, and no outbreak was detected during the study period. However, infections caused by B. cepacia should be taken into consideration because of their high mortality due to multidrug resistance in ICU settings.


Asunto(s)
Infecciones por Burkholderia/epidemiología , Burkholderia cepacia/aislamiento & purificación , Infección Hospitalaria/epidemiología , Adulto , Anciano , Antibacterianos/farmacología , Antibacterianos/uso terapéutico , Infecciones por Burkholderia/tratamiento farmacológico , Infecciones por Burkholderia/microbiología , Infecciones por Burkholderia/mortalidad , Burkholderia cepacia/efectos de los fármacos , Infección Hospitalaria/tratamiento farmacológico , Infección Hospitalaria/microbiología , Infección Hospitalaria/mortalidad , Femenino , Hospitales Universitarios , Humanos , Incidencia , Masculino , Pruebas de Sensibilidad Microbiana , Persona de Mediana Edad , Resultado del Tratamiento , Turquía , Adulto Joven
5.
Braz. j. infect. dis ; 12(5): 395-399, Oct. 2008. ilus, tab
Artículo en Inglés | LILACS | ID: lil-505353

RESUMEN

We investigated a nosocomial cluster of four Candida parapsilosis fungemia episodes that occurred in a neurological intensive care unit over a two-week period. The four infected patients had received parenteral nutrition through central lines, and all four had catheter-related candidemia. All of the isolates were susceptible to all of the antifungals tested, including amphotericin B, fluconazole, voriconazole, and caspofungin. They had strictly related fingerprints, based on randomly amplified polymorphic DNA analysis. Additional DNA sequencing data revealed that they were same strain. Although no isolate of Candida parapsilosis was recovered from other clinical, surveillance, or environmental samples, nosocomial spread of this yeast ceased, following the reinforcement of infection-control measures. Candida parapsilosis may require an intravascular foreign body to cause fungemia, but this outbreak shows that it can be transmitted nosocomially and can cause epidemics.


Asunto(s)
Anciano , Femenino , Humanos , Masculino , Candida/genética , Candidiasis/microbiología , Infección Hospitalaria/microbiología , Brotes de Enfermedades , Fungemia/microbiología , Antifúngicos/farmacología , Brasil , Candida/clasificación , Candida/efectos de los fármacos , Candidiasis/epidemiología , Cateterismo/efectos adversos , Infección Hospitalaria/epidemiología , ADN de Hongos/análisis , Fungemia/epidemiología , Unidades de Cuidados Intensivos , Técnicas de Tipificación Micológica/métodos , Nutrición Parenteral/instrumentación , Técnica del ADN Polimorfo Amplificado Aleatorio , Estudios Retrospectivos , Factores de Riesgo
6.
Braz J Infect Dis ; 12(5): 395-9, 2008 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-19219279

RESUMEN

We investigated a nosocomial cluster of four Candida parapsilosis fungemia episodes that occurred in a neurological intensive care unit over a two-week period. The four infected patients had received parenteral nutrition through central lines, and all four had catheter-related candidemia. All of the isolates were susceptible to all of the antifungals tested, including amphotericin B, fluconazole, voriconazole, and caspofungin. They had strictly related fingerprints, based on randomly amplified polymorphic DNA analysis. Additional DNA sequencing data revealed that they were same strain. Although no isolate of Candida parapsilosis was recovered from other clinical, surveillance, or environmental samples, nosocomial spread of this yeast ceased, following the reinforcement of infection-control measures. Candida parapsilosis may require an intravascular foreign body to cause fungemia, but this outbreak shows that it can be transmitted nosocomially and can cause epidemics.


Asunto(s)
Candida/genética , Candidiasis/microbiología , Infección Hospitalaria/microbiología , Brotes de Enfermedades , Fungemia/microbiología , Anciano , Antifúngicos/farmacología , Brasil , Candida/clasificación , Candida/efectos de los fármacos , Candidiasis/epidemiología , Cateterismo/efectos adversos , Infección Hospitalaria/epidemiología , ADN de Hongos/análisis , Femenino , Fungemia/epidemiología , Humanos , Unidades de Cuidados Intensivos , Masculino , Técnicas de Tipificación Micológica/métodos , Nutrición Parenteral/instrumentación , Técnica del ADN Polimorfo Amplificado Aleatorio , Estudios Retrospectivos , Factores de Riesgo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...